	US 12,214,028 B2
	*Immunogenic formulation that induces protection against shiga toxin-producing Escherichia coli* (STEC)**
Roberto Mauricio Vidal Alvarez, Santiago (CL); Felipe Antonio Del Canto Fuentes, Santiago (CL); David Arturo Montero Forero, Santiago (CL); and Juan Carlos Salazar Garrido, Santiago (CL)
Assigned to UNIVERSIDAD DE CHILE, Santiago (CL)
Appl. No. 17/615,554
Filed by UNIVERSIDAD DE CHILE, Santiago (CL)
PCT Filed May 31, 2019, PCT No. PCT/IB2019/054554 § 371(c)(1), (2) Date Nov. 30, 2021, PCT Pub. No. WO2020/240268, PCT Pub. Date Dec. 3, 2020.
Prior Publication US 2022/0233672 A1, Jul. 28, 2022
Int. Cl. A61K 39/02 (2006.01); A61K 39/108 (2006.01); A61K 47/64 (2017.01); A61K 47/69 (2017.01); A61P 31/04 (2006.01); C07K 14/245 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/0258 (2013.01) [A61K 47/6415 (2017.08); A61K 47/6917 (2017.08); A61P 31/04 (2018.01); C07K 14/245 (2013.01); A61K 2039/575 (2013.01)]

9 Claims

1. An immunogenic formulation that induces protection against shiga Toxin-Producing Escherichia coli (STEC), the formulation comprising:

(i) a chimeric protein derived from OmpT and Hes proteins of STEC, having the amino acid sequence as set forth in SEQ ID NO: 1;

(ii) a second chimeric protein derived from α-Cah protein of STEC, having the amino acid sequence as set forth in SEQ ID NO: 2; and

(iii) at least one physiologically or pharmaceutically acceptable excipient, carrier and/or diluent.